Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Antiplatelet Trialist’ Collaboration: Collaborative overview of randomised trials of antiplatelet therapy: I.
Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.
Br Med J, 308 (1994), pp. 81-106
[2.]
P.A. Jänne, R.J. Mayer.
Chemoprevention of colorectal cancer.
N Engl J Med, 342 (2000), pp. 1960-1968
[3.]
A. Lanas, E. Bajador, P. Serrano, J. Fuentes, S. Carreño, J. Guardia, et al.
Nitrovasodilators, low-dose aspirin, nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding.
N Engl J Med, 343 (2000), pp. 834-839
[4.]
J. Weil, D. Colin Jones, M.J.S. Langman, D. Lawson, R. Logan, M. Murphy, et al.
Prophylactic aspirin and risk of peptic ulcer bleeding.
BMJ, 310 (1995), pp. 827-830
[5.]
A. Lanas, J. Fuentes, R. Benito, E. Bajador, P. Serrano, R. Sainz.
Helicobacter pylori increases the risk of gastrointestinal bleeding in patients taking low dose aspirin.
Gastroenterology, 118 (2000), pp. A252
[6.]
C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, D. Davis, et al.
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
N Engl J Med, 343 (2000), pp. 1520-1528
[7.]
F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, et al.
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
JAMA, 284 (2000), pp. 1247-1255
[8.]
F.K.L. Chan, J.J. Sung, B.Y. Suen, J.C. Wu, V.K. Leung, M.S. Lai, et al.
Prospective randomized trial of H. pylori eradication versus maintenance omeprazole to prevent recurrent upper gastrointestinal hemorrhage in high-risk aspirin and non-aspirin NSAID users [resumen].
Gastroenterology, 118 (2000), pp. 1228
[9.]
J. López-Belmonte, B.J.R. Whittle, S. Moncada.
The actions of nitric oxide donors in the prevention or induction of injury to the rat gastric mucosa.
Br J Pharmacol, 108 (1993), pp. 73-78
[10.]
J.L. Wallace.
Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years.
Gastroenterology, 112 (1997), pp. 1000-1016
[11.]
M.D. Barrachina, S. Calatayud, A. Canet, R. Bello, F. Díaz de Rojas, P.H. Guth, et al.
Transdermal nitroglycerin prevents gastric damage induced by nonsteroidal-antiinflammatory drugs and bile salts.
Eur J Pharmacol, 281 (1995), pp. R3-R4
[12.]
J.L. Wallace, M.N. Muscara, W. McKnight, M. Dicay, P. Del Soldato, G. Cirino.
In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016.
Thromb Res, 93 (1999), pp. 43-50
[13.]
M.N. Muscara, W. McKnight, F. Lovren, C.R. Triggle, G. Cirino, J.L. Wallace.
Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats.
Am J Physiol Heart Circ Physiol, 279 (2000), pp. H528-H535
[14.]
M.T. Donnelly, W.A. Stack, E.M. Courtauld, N. Garlick, P. Del Soldato, C.J. Hawkey.
Nitric oxide donating flurbirpofen (HCT 1026) causes less endoscopic damage in healthy volunteers than flurbiprofen.
Gastroenterology, 114 (1998), pp. G0441
[15.]
García-Rodríguez LA, Hernández-Díaz S. The relative risk of upper gastrointestinal complications among users of acetaminophen and non-steroidal anti-inflammatory drugs. Epidemiology. En prensa
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
